3138013-03-0
Chemical Structure
P-SiaFNEtoc
- CAS. Nr.: 3138013-03-0
- Formula:C23H32FNO15
- Molecular Weight:581.50
SMILES: COC(C1(O[C@@]([C@@H]([C@H]([C@H]1F)OC(C)=O)NC(OCC)=O)([H])[C@H](OC(C)=O)[C@H](OC(C)=O)COC(C)=O)OC(C)=O)=O
Biological Activity: P-SiaFNEtoc is a Sialyltransferase inhibitor that blocks sialic acid capping of glycans. P-SiaFNEtoc forms CMP-SiaFNEtoc, reduces endogenous CMP-Neu5Ac, feedback-inhibits GNE, and depletes sialylation on N-glycans and O-GalNAc glycans. P-SiaFNEtoc decreases cell surface sialoglycan levels, VEGF and DKK-1 secretion, Tn antigen levels, and cell cycle checkpoint/E2F target gene expression, while inducing p27/Kip1 and fucosylation. P-SiaFNEtoc can be used in research on prostate cancer, and melanoma[1][2][3][4][5].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
P-SiaFNEtoc | P-SiaFNEtoc is a Sialyltransferase inhibitor that blocks sialic acid capping of glycans. P-SiaFNEtoc forms CMP-SiaFNEtoc, reduces endogenous CMP-Neu5Ac, feedback-inhibits GNE, and depletes sialylation on N-glycans and O-GalNAc glycans. P-SiaFNEtoc decreases cell surface sialoglycan levels, VEGF and DKK-1 secretion, Tn antigen levels, and cell cycle checkpoint/E2F target gene expression, while inducing p27/Kip1 and fucosylation. P-SiaFNEtoc can be used in research on prostate cancer, and melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hodgson K, et al. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. EBioMedicine. 2024 Jun;104:105163.
- [2]. Orozco-Moreno M, et al. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology. 2023 Dec 30;33(12):1155-1171.
- [3]. Visser EA, et al. Investigating the utilization mechanism and kinetics of sialic acid mimetics in mammalian cell lines. RSC chemical biology. 2026 Jan 14;7(1):144-152.
- [4]. Moons SJ, et al. UV light-induced spatial loss of sialic acid capping using a photoactivatable sialyltransferase inhibitor. RSC chemical biology. 2023 Jul 05;4(7):506-511.
- [5]. Goode EA, et al. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. Cancers (Basel). 2024 Aug 24;16(17):2953. [Content Brief]
